vestimИзвестия Национальной академии наук Беларуси. Серия медицинских наукProceedings of the National Academy of Sciences of Belarus, Medical series1814-60232524-2350The Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"vestim-351Research ArticleКЛИНИЧЕСКАЯ И ЭКСПЕРИМЕНТАЛЬНАЯ МЕДИЦИНАCLINICAL AND EXPERIMENTAL MEDICINEПРОГНОСТИЧЕСКОЕ ЗНАЧЕНИЕ МЕТИЛИРОВАНИЯ ГЕНА REPRIMO У ПАЦИЕНТОВ С РЕЗЕКТАБЕЛЬНЫМ РАКОМ ЖЕЛУДКАPROGNOSTIC VALUE OF REPRIMO METHYLATION IN PATIENTS WITH RESECTABLE GASTRIC CANCERРевтовичМ. Ю.ReutovichM. Yu.

канд. мед. наук, доцент.

Ph. D. (Med.), Associate Professor.

mihail_revtovich@yahoo.comШмакА. И.ShmakA. I.

д-р мед. наук, зав. лабораторией.

D. Sc. (Med.), Head of the Laboratory.

smak.ai@tut.byКраськоО. В.KraskoO. V.

канд. техн. наук, доцент, вед. науч. сотрудник

Ph. D. (Techn.), Associate Professor, Leading researcher.

krasko@newman.bas-net.byСмоляковаР. М.SmolyakovaR. M.

д-р биол. наук, доцент, заведующий лабораторией.

D. Sc. (Biol.), Associate Professor, Head of the Laboratory

smol60@mail.ruБабенкоА. С.BabenkoA. S.

канд. хим. наук, заведующий отделением.

Ph. D. (Chem.), Head of the Department.

labmdbt@gmail.comРеспубликанский научно-практический центр онкологии и медицинской радиологии им. Н. Н. АлександроваБеларусьN. N. Alexandrov National Cancer CentreBelarusОбъединенный институт проблем информатики НАН БеларусиБеларусьUnited Institute of Informatics Problems of the National Academy of Sciences of BelarusBelarus201701032017016677Copyright © Ревтович М.Ю., Шмак А.И., Красько О.В., Смолякова Р.М., Бабенко А.С., 20172017Ревтович М.Ю., Шмак А.И., Красько О.В., Смолякова Р.М., Бабенко А.С.Reutovich M.Y., Shmak A.I., Krasko O.V., Smolyakova R.M., Babenko A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestimed.belnauka.by/jour/article/view/351

Статус метилирования гена Reprimo определен в первичной опухоли и в смывах с брюшины до и после лимфодиссекции при радикальном хирургическом лечении рака желудка. Анализ статуса Reprimo в смывах у пациентов до и после лимфодиссекции показал статистически значимые его изменения (p  =� 0,007) и продемонстрировал сопря-  сопряженность этого статуса в первичной опухоли cо степенью метастатического поражения регионарного лимфоколлектора pN (p  = 0,043). С помощью многофакторного анализа определены также риски диссеминации, прогрессированияи выживаемости, связанные со статусом Reprimo в опухоли, смывах после операции и степенью метастатического поражения регионарного лимфоколлектора (pN). Полученные данные позволяют рассматривать положительный статус метилирования Reprimo в качестве дополнительного критерия при определении показаний для проведения адъювантной химиотерапии.

The Reprimo gene methylation status is identified in primary tumors and peritoneal washings after radical surgical treatment of gastric cancer. The analysis allowed us to show a statistically significant change in the Reprimo status in peritoneal washings in patients before and after dissection (p  = 0.007) and also to identify the conjugation of the Reprimo status in the primary tumor with the number of the metastatic lymph node pN (p  = 0.043). The risk of disease progression with peritoneal dissemination and survival linked with the Reprimo tumor status, with the Reprimo status of peritoneal washings, and with lymph node metastases (pN) are identified using the multivariate analysis. The data allow us to consider the methylation status Reprimo as an additional indication for adjuvant intraperitoneal chemotherapy.

рак желудкастатус метилирования гена Reprimoперитонеальная диссеминацияgastric cancerReprimo gene methylation statusperitoneal disseminationReferencesAberrant methylation of Reprimo in human malignancies / T. Takahashi [et al.] // Int. J. Cancer. – 2005. – Vol. 115. – P. 503–510.Takahashi T., Suzuki M., Shigematsu H., Shivapurkar N., Echebiri C., Nomura M., Stastny V., Augustus M., Wu C. W., Wistuba I. I., Meltzer S. J., Gazdar A. F. “Aberrant methylation of Reprimo in human malignancies”, Inernational Journal of Cancer, 2005, vol. 115, pp. 503–510.Loss of Expression of Reprimo, a p53-induced Cell Cycle Arrest Gene, Correlates with Invasive Stage of Tumor Progression and p73 Expression in Gastric Cancer [Electronic resourse] / K. Saavedra [et al.] // PLoS One. – 2015. – Vol. 10gastric cancer, Reprimo gene methylation status, peritoneal dissemination.(5):e0125834. – Mode of access: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0125834. – Date of access: 08.05.2016.Saavedra K., Valbuena J., Olivares W., Marchant M. J., Rodríguez A., Torres-Estay V., Carrasco-Avino G., Guzmán L., Aguayo F., Carlos Roa J., Corvalán A. H. “Loss of Expression of Reprimo, a p53-induced Cell Cycle Arrest Gene, Correlates with Invasive Stage of Tumor Progression, p73 Expression in Gastric Cancer”, PLoS One, 2015, vol. 10 (5), pp. e0125834, Available at: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0125834 (Accessed 08.05.2016).Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma / N. Sato [et al.] // Cancer. – 2006. – Vol. 107, N 2. – P. 251–257.Sato N., Fukushima N., Matsubayashi H., Iacobuzio-Donahue C. A., Yeo C. J., Goggins M. “Aberrant methylation of Reprimo correlates with genetic instability, predicts poor prognosis in pancreatic ductal adenocarcinoma”, Cancer, 2006, vol. 107, no. 2, pp. 251–257.Clopper, C. J. The use of confidence or fiducial limits illustrated in the case of the binomial / C. J. Clopper, E. S. Pearson // Biometrika. – 1934. – Vol. 26. – P. 404–413.Clopper C. J., Pearson E. S. “The use of confidence or fiducial limits illustrated in the case of the binomial”, Biometrika, 1934, vol. 26, pp. 404–413.R Core Team (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.“R Core Team (2016). “R: A language, environment for statistical computing. R Foundation for Statistical Computing”, Vienna, Austria, URL, Available at: https://www.R-project.org/ (Accessed 08.05.2016).Therneau, T. A рackage for survival analysis in S_ version 2.38 [Electronic resourse] / T. Therneau. – 2015. – Mode of access: http://CRAN.R-project.org/package=survival>. – Date of access: 12.09.2016.Therneau T. “A рackage for survival analysis in S_ version 2.38”, 2015, Available at: http://CRAN.R-project.org/package=survival> (Accessed 12.09.2016).Genetic detection of free cancer cells in the peritoneal cavity of the patient with gastric cancer: present status and future perspectives / Y. Fujiwara [et al.] // Gastric Cancer. – 2007. – Vol. 10. – P. 197–204.Fujiwara Y., Doki Y., Taniguchi H., Sohma I., Takiguchi S., Miyata H., Yamasaki M., Monden M. “Genetic detection of free cancer cells in the peritoneal cavity of the patient with gastric cancer: present status, future perspectives”, Gastric Cancer, 2007, vol. 10, pp. 197–204.DNA damage-inducible gene, Reprimo functions as a tumor suppressor and is suppressed by promoter methylation in gastric cancer / A. Ooki [et al.] // Mol. Cancer Res. – 2013. – Vol. 11, N 11. – P. 1362–1374.Ooki A., Yamashita K., Yamaguchi K., Mondal A., Nishimiya H., Watanabe M. “DNA damage-inducible gene, Reprimo functions as a tumor suppressor, is suppressed by promoter methylation in gastric cancer”, Molecular Cancer Research, 2013, vol. 11, no. 11, pp. 1362–1374.Loss of Reprimo and S100A2 expression in human gastric adenocarcinoma / J. Luo [et al.] // Diag. cytopathol. – 2011. – Vol. 39, N 10. – P. 752–757.Luo J., Zhu Y., Yang G., Gong L., Wang B., Liu H. “Loss of Reprimo, S100A2 expression in human gastric adenocarcinoma”, Diagnostic cytopathology, 2011, vol. 39, no. 10, pp. 752–757.Mechanisms of peritoneal metastasis after operation for non-serosa invasive gastric carcinoma: an ultrarapid detection system for intraperitoneal free cancer cells and a prophylactic strategy for peritoneal metastasis / T. Marutsuka [et al.] // Clin. Cancer Res. – 2003. – Vol. 9. – P. 678–685.Marutsuka T., Shimada S., Shiomori K., Hayashi N., Yagi Y., Yamane T., Ogawa M. “Mechanisms of peritoneal metastasis after operation for non-serosa invasive gastric carcinoma: an ultrarapid detection system for intraperitoneal free cancer cells, a prophylactic strategy for peritoneal metastasis”, Clinical Cancer Research, 2003, vol. 9, no. 2, pp. 678–685.Lymph node metastasis as a significant prognostic factor in gastric cancer: a multiple logistic regression analysis /T. Yokota [et al.] // Scand. J. Gastroenterol. – 2004. – Vol. 39. – P. 380–384.Yokota T., Ishiyama S., Saito T., Teshima S., Narushima Y., Murata K., Iwamoto K., Yashima R., Yamauchi H., Kikuchi S. “Lymph node metastasis as a significant prognostic factor in gastric cancer: a multiple logistic regression analysis”, Scandinavian Journal of Gastroenterology, 2004, vol. 39, no. 4, pp. 380–384.Peritoneal washing cytology: prognostic value of positive findings in patients with gastric carcinoma undergoing a potentially curative resection / Y. Kodera [et al.] // J. Surg. Oncol. – 1999. – Vol. 72. – P. 60–65.Kodera Y., Yamamura Y., Shimizu Y., Torii A., Hirai T., Yasui K., Morimoto T., Kato T. “Peritoneal washing cytology: prognostic value of positive findings in patients with gastric carcinoma undergoing a potentially curative resection”, Journal of Surgical Oncology, 1999, vol. 72, pp. 60–65.Japanese Gastric Cancer Association Japanese classification of gastric carcinoma. 2nd English ed. // Gastric Cancer. – 2011. – Vol. 14. – P. 101–112.“Japanese Gastric Cancer Association Japanese classification of gastric carcinoma, 2nd English ed.”, Gastric Cancer, 2011, vol. 14, pp. 101–112.Preoperative intraperitoneal chemotherapy for patients with serosa-infiltrating gastric cancer / M. Yano [et al.] //J. Surg. Oncol. – 2004. – Vol. 88. – P. 39–43.Yano M., Yasuda T., Fujiwara Y., Takiguchi S., Miyata H., Monden M. “Preoperative intraperitoneal chemotherapy for patients with serosa-infiltrating gastric cancer”, Journal of Surgical Oncology, 2004, vol. 88, no. 1, pp. 39–43.

The authors declare that there are no conflicts of interest present.